Abeona Therapeutics (ABEO) Updates Clinical Data from Phase 1/2 Trial for EB-101 Gene Therapy in Epidermolysis Bullosa
Tweet Send to a Friend
Abeona Therapeutics Inc. (NASDAQ: ABEO) announced today updated clinical data from the Phase 1/2 trial for EB-101, the company’s gene-corrected ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
